ABSTRACT
Background
Skin aging is a complex process influenced by genetic, hormonal, and environmental factors. Exosome‐based therapies, particularly those derived from plant sources such as apples, have emerged as a promising alternative for promoting skin regeneration and improving skin health.
Methods
A 12‐week prospective, non‐randomized, split‐face, self‐controlled trial was conducted with 21 participants aged 40–59 years. The right facial hemisphere received Exo‐V Professional combined with Microneedle Therapy System (MTS), while the left hemisphere was treated with microneedling and normal saline as a control. This side allocation was predefined and was not randomized. Participants underwent four treatment sessions at three‐week intervals. Skin improvement was assessed through objective measurements, including wrinkle depth, skin lifting, skin elasticity, hydration, skin brightness, pore size, texture, glossiness, and transepidermal water loss (TEWL). Histopathological evaluation was performed on ex vivo human skin samples to assess collagen synthesis. Subjective satisfaction was measured using a 5‐point Likert scale, and adverse reactions were monitored through clinical assessments.
Results
The Exo‐V side exhibited significantly greater improvements in all measured parameters compared to the control side (p < 0.05). Histological analysis confirmed enhanced collagen deposition in the Exo‐V side, with increased young collagen synthesis compared to the control. Subjective assessments showed 100% participant satisfaction, with no reported adverse skin reactions throughout the study.
Conclusion
Exo‐V Professional applied after microneedling was associated with greater short‐term improvements in multiple facial skin parameters than microneedling with saline, suggesting its potential as a topical adjunctive approach for facial rejuvenation. Further randomized, blinded, vehicle‐controlled studies with longer follow‐up are needed to confirm these findings, clarify the underlying mechanisms, and assess the durability of the observed effects.
Keywords: anti‐aging, apple‐derived exosome, collagen synthesis, microneedle, skin rejuvenation
1. INTRODUCTION
The skin is the largest organ in the human body, composed by the epidermis, dermis, subcutaneous tissue, and skin appendages [1, 2]. Skin aging is a multifactorial process influenced by both intrinsic and extrinsic factors, leading to significant changes in anatomical structure [3]. Intrinsic factors of skin aging include genetics, hormone levels, and metabolic status, which are mainly manifested as the decline in function at cellular level. Extrinsic factors are mainly environmental pollution, smoking and ultraviolet (UV) radiation, among which photoaging is the most important external factor accounting for about 80% of facial aging [4]. UV radiation can damage the DNA of skin cells, causing permanent damage, manifested as wrinkles, pigmentation, sagging skin, rough texture, capillary dilation, and may even cause skin cancer [5].
With the rapid development of society, the demand for improvements of skin, especially facial rejuvenation, has grown significantly. Current methods for facial rejuvenation include botulinum toxin injections, filler injections, chemical peels, laser and radiofrequency therapies, and surgical procedures [6, 7]. Many of these approaches may be costly, invasive, or associated with variable outcomes and recovery periods. Microneedling is comparatively less invasive and generally associated with shorter downtime than ablative resurfacing procedures, although repeated sessions may be required and transient erythema, edema, discomfort, or irritation can occur [8].
Exosomes are lipid bilayer nanovesicles containing specific nucleic acids and proteins that facilitate cell‐to‐cell communication in both prokaryotic and eukaryotic organisms, regulating numerous biological processes [9]. Their therapeutic potential has attracted widespread research attention in recent years. In facial rejuvenation, mesenchymal stem cell‐derived exosomes, particularly from adipose tissue, have shown promise by promoting wound healing, tissue regeneration, and modulating inflammatory responses [10, 11, 12]. However, many of these manufacturing and translational limitations pertain primarily to mammalian, especially mesenchymal stem cell‐derived exosomes, including source variability, isolation complexity, standardization difficulties, and cost [13, 14]. By contrast, plant‐derived exosome‐like nanovesicles may offer advantages such as lower immunogenicity and improved scalability, although they also face important challenges, including heterogeneity, incomplete standardization of isolation and characterization methods, and the need for further mechanistic and quality‐control studies [15]. Studies demonstrate that exosomes from rose [16], ginseng [17], yam [13], and apple [18] possess anti‐aging properties. Apple‐derived exosomes specifically activate THP‐1‐derived macrophages by regulating miR‐146a, exhibiting anti‐inflammatory activity [19]. They also promote type I collagen production while downregulating NF‐κB, thereby counteracting skin aging [18].
Exo‐V Professional is a commercially available two‐component topical formulation designed for facial application. It contains Malus domestica fruit cell extract derived from a plant callus culture system, which may provide a more reproducible and standardized bioactive source than conventional raw botanical extracts that are affected by seasonal and geographic variation. The product consists of a lyophilized powder and an activating solution, with apple‐derived exosome‐like components listed as the principal ingredient in the lyophilized component. To our knowledge, this study represents the first prospective clinical evaluation of Exo‐V Professional for facial rejuvenation under microneedling‐assisted application conditions.
In addition to the drug composition itself, the drug delivery system also plays a critical role in facial rejuvenation treatments. The microneedle therapy system (MTS) is a minimally invasive method that uses multiple micron‐sized needles to penetrate the skin epidermis and create micropores, allowing drugs to effectively diffuse into the dermis [20]. Furthermore, MTS stimulates the skin repair processes through skin puncturing, promoting collagen reproduction and improving skin elasticity, wrinkles, and other concerns [8].
This study prospectively enrolled 21 participants and compared the effects of the MTS treatment side with the MTS + Exo‐V Professional treatment side. Various facial skin conditions were assessed, including wrinkle improvement, lifting, elasticity, hydration, brightness, pore size, texture, gloss, and transepidermal water loss (TEWL). The results showed significant improvements in the MTS + Exo‐V Professional treatment side across all these parameters. This study provides reliable evidence supporting the clinical application of apple‐derived exosomes combined with the MTS in facial rejuvenation.
2. MATERIALS AND METHODS
2.1. Study Design
This study is a 12‐week prospective, non‐randomized, split‐face, self‐controlled trial comparing the effects of the test product (Exo‐V Professional) combined with MTS versus MTS alone on skin condition. The study was approved by the Institutional Review Board (IRB) of the Korea Skin Clinical Research Center (KSRC) (Approval No: HBABN01‐241016‐HR‐E0044‐04) and was conducted in strict accordance with the ethical principles outlined in the Declaration of Helsinki.
Participants were recruited through public advertisements at local hospitals and offline platforms, and all were formally enrolled after providing written informed consent. The study was conducted in Seoul, South Korea, from November 11, 2024, to February 3, 2025, covering the autumn and winter seasons, with temperatures ranging from ‐12°C to 15°C.
2.2. Test Product
Exo‐V Professional is a two‐component product comprising a lyophilized powder (Component 1) and a transparent liquid solution (Component 2). Component 1 contains apple‐derived exosomes (95%), ascorbic acid (1%), mannitol (2%), and purified water (2%), while Component 2 is composed of sodium DNA (purified salmon sperm DNA), sodium hyaluronate, sodium bicarbonate, water‐soluble proteoglycan, and purified water. Component 2 is supplied as a 3 mL solution. The preparation protocol involves transferring the transparent solution (Component 2) into the lyophilized powder (Component 1) and thoroughly mixing until complete dissolution. The resulting homogeneous solution is subsequently applied to the designated facial test area. Throughout the study, stringent management protocols were implemented, including comprehensive documentation of study identification numbers, product specifications, and sample storage metadata. All test products were stored in a temperature‐controlled environment at 4 ± 2°C and relative humidity of 40%–60%, protected from direct light and contamination. A predetermined disposal policy was applied: all unused or remaining samples were scheduled for disposal three years after the official completion date of the study, in accordance with the internal biocompatibility safety protocol and institutional regulations. Because this is a commercially available formulation, the exact final concentration of each ingredient after reconstitution is proprietary and was not fully disclosed by the manufacturer.
2.3. Study Participants
The study enrolled healthy male and female adults aged 40–59 years with no discernible facial skin abnormalities, including lesions, scars, or tattoos, who demonstrated the ability to adhere to comprehensive follow‐up protocols. Stringent exclusion criteria were implemented to ensure participant safety and study integrity. These criteria encompassed physiological states such as pregnancy, lactation, or potential conception plans; dermatological history including eczema, psoriasis, or skin malignancies; chronic metabolic or cardiovascular conditions like diabetes and hypertension; recent pharmacological interventions involving antibiotics, immunomodulatory agents, or topical corticosteroids; recent aesthetic procedures including laser therapies or tanning; and prior participation in comparable clinical investigations within the preceding month. Participant withdrawal was mandated under specific circumstances: experiencing adverse reactions precluding continued participation, voluntary discontinuation, or investigator‐determined unsuitability based on concomitant medication use, concurrent clinical study enrollment, or consistent failure to complete scheduled follow‐up assessments. In this study, the sample size was determined pragmatically with reference to the Guidelines for Cosmetic Labeling and Advertising Verification Trials, which recommend a minimum of 20 participants for this type of human application study. No formal a priori sample size calculation based on type I error, effect size, and statistical power was performed. To allow for possible dropout, 24 participants were initially enrolled.
2.4. Treatment Protocol
Prior to the trial, participants underwent a standardized pre‐treatment protocol involving facial cleansing and acclimatization in a precisely controlled environmental chamber (temperature: 22 ± 2°C, relative humidity: 50 ± 5%) for 20–30 min. A formal wash‐off period was not included before treatment initiation. However, participants who had recently undergone cosmetic procedures, laser treatment, tanning, or comparable clinical studies were excluded. During the study period, participants were instructed not to initiate new functional cosmetics, anti‐aging products, exfoliating agents, whitening products, retinoids, or other topical products that could affect skin texture, hydration, pigmentation, or barrier function. Only basic daily skincare products, including gentle cleansers, moisturizers, and sunscreen, were permitted to maintain routine skin care and minimize irritation during follow‐up. During each treatment session, the right facial hemisphere received Exo‐V Professional combined with microneedling (Dr. Back 10 StoryFNS FN‐1, Dongbang Medi‐care, Seoul), while the contralateral side was treated with microneedling and normal saline solution as a control intervention. Microneedling was consistently performed at a standardized depth of 1 mm. Because no random allocation was performed, the study should be interpreted as a non‐randomized self‐controlled intervention study. To improve measurement consistency, all instrumental assessments were conducted under standardized environmental conditions using prespecified devices and protocols.
The study employed a comprehensive longitudinal assessment protocol with multiple evaluation phases: Baseline (pre‐intervention), first Evaluation Phase (immediately post‐initial treatment), second Evaluation Phase (three weeks post‐first treatment), third Evaluation Phase (three weeks post‐second treatment), fourth Evaluation Phase (three weeks post‐third treatment), and Final Evaluation Phase (three weeks post‐fourth treatment). This split‐face experimental design was replicated across four treatment sessions over a total duration of 12 weeks, encompassing five distinct evaluation time points to assess the product's efficacy and safety profile comprehensively.
2.5. Objective Assessment of Skin Improvement
2.5.1. Wrinkle Improvement Assessment
Wrinkle improvement was evaluated using the Antera 3D CS device (Miravex Limited, Ireland) in Wrinkle Mode, which analyzes skin wrinkle parameters (unit: mm). This assessment was conducted through three‐dimensional (3D) reconstruction technology with multi‐directional illumination, allowing for precise measurement of the skin's surface topography and wrinkle depth.
2.5.2. Skin Lifting Effect Assessment
Skin lifting effects were evaluated using the F‐RAY device (BEYOUNG, South Korea), which generates facial contour images based on the Moire interference phenomenon. The contour angles (unit: °) were analyzed using Image‐Pro 10 software (Media Cybernetics, USA) to assess skin firmness and lifting effects.
2.5.3. Skin Elasticity Assessment
Skin elasticity was assessed using the Cutometer MPA580 device (C+K, Germany). The device applied a constant negative pressure of 450 mbar, performing three consecutive suction cycles, each lasting 2 s. Skin elasticity was quantified using the R2 value, which represents the skin's ability to return to its original state after deformation.
2.5.4. Moisturizing Effect Assessment
Moisturizing effects were evaluated using the Corneometer CM 825 device (C+K, Germany). Measurements were taken three times at the test site, and the average value was recorded. The device assesses stratum corneum hydration levels by generating an electric field through its probe and calculating capacitance (A.U.) changes. Higher values indicate higher skin hydration.
2.5.5. Skin Tone (Brightness) Assessment
Skin brightness was assessed using the VISIA CR device under standard light mode for imaging, followed by three measurements with the Spectrophotometer CM26dG (Minolta, Japan). The average L‐value was calculated based on the CIE Lab color space, where a higher L‐value indicates a brighter complexion.
2.5.6. Pore Area Assessment
Pore area was assessed using the Antera 3D CS device in Pore Mode, which measured the Mean Pore Area (unit: mm2). The device analyzed the total pore‐occupied area within a selected region to quantify changes in pore size and distribution.
2.5.7. Skin Texture Assessment
Skin texture was evaluated using the Antera 3D CS device in Texture Mode, which measured the Ra value (surface roughness, unit: µm). The Ra value represents the average roughness of the skin surface, with lower values indicating a smoother skin texture.
2.5.8. Skin Glossiness (Radiance) Assessment
Skin gloss was evaluated using the Skin‐Glossymeter GL 200 (Delfin Technologies Ltd, Finland). Measurements were taken three times at the test site, and the average G.U (Gloss Unit) was calculated. The device assesses skin glossiness based on the principle of light reflection, measuring the reflectance of the skin surface to determine its luminance and hydration‐related shine.
2.5.9. TEWL Assessment
TEWL was assessed using the Tewameter TM HEX (C+K, Germany). Measurements were taken three times at the test site, and the average TEWL value was calculated, expressed in g/m2/h. This evaluation quantifies the skin barrier function, with higher TEWL values indicating increased water loss and impaired barrier integrity.
All measurements were conducted using standardized methods to ensure data accuracy and comparability. The following formula was used to calculate the relative percentage change in each evaluation parameter before and after product application, quantifying the product's efficacy: Change rate (%) = (baseline value—value at the nth evaluation phase) / baseline value, n = 1,2,3,4,5.
2.6. Subjective Satisfaction Score
Following the 12‐week product evaluation period, participants assessed the product's efficacy and user experience using a standardized 5‐point Likert scale with the following categorical descriptors: 1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied. Responses with scores of 3–5 were considered positive feedback. Before completing the survey, participants received standardized verbal instructions to ensure a consistent and accurate understanding of each Likert scale point, thereby minimizing subjective bias or misinterpretation in their responses.
The positive feedback rate (%) was calculated as follows:
Positive Feedback Rate (%) = the Number of Participants Who Rated the Product 3, 4, or 5/Total Number of Participants × 100%.
2.7. Assessment of Adverse Skin Reactions
Throughout each evaluation phase, investigators meticulously examined participant test sites and conducted comprehensive clinical interviews to systematically document and evaluate any newly emerging adverse reactions. The surveillance protocol encompassed a comprehensive assessment of dermatological manifestations, including erythema, pigmentation alterations, edema, ecchymosis, and scab formation. Skin conditions were rigorously documented using standardized clinical observation protocols. In the event of a participant experiencing an adverse reaction potentially associated with the test product, investigators were mandated to complete a detailed Adverse Reaction Report. These reports underwent a thorough review by the study director to establish a causal relationship between the observed reaction and the investigational product.
2.8. Ex Vivo Experiment and Histopathological Evaluation
An ex vivo skin model was used for histopathological assessment. The study utilized discarded human skin tissues from breast reconstruction procedures in adults (20‐60 years), with approval by the Institutional Review Board of the Korean Institute of Nonclinical Study (KINS) (Approval No: B‐2404‐893‐301). Following dual phosphate‐buffered saline rinses, tissues were transferred to sterile petri dishes, sectioned into 2 cm × 2 cm specimens, and sampled using an 8 mm biopsy punch (KAI Medical, Japan). To maintain physiological conditions, specimens were cultured in a Transwell system (6‐well plate), with culture medium (DMEM/F12 [1:1], supplemented with 2% FBS, 1% penicillin‐streptomycin, 2 mM L‐glutamine, 0.5 µg/mL hydrocortisone, and other components; all from Gibco, Thermo Fisher Scientific, USA) in the lower chamber. The skin samples were positioned on Transwell inserts (Corning, USA) for the duration of the experimental culture period.
The study comprised two sides: a control side and an experimental side, both receiving microneedling stimulation via MTS (Skin Mode: operational parameters set at Speed 90, Depth 0.5 mm, applied for 1 min). The control side received normal saline application (100 µL), while the experimental side was treated with Exo‐V Professional (100 µL). Tissue specimens were collected at three predefined time points (Day 0, Day 3, and Day 7) to evaluate the temporal impact of Exo‐V Professional on cutaneous tissue responses.
The harvested specimens underwent fixation in 10% formalin, paraffin embedding, and sectioning to 3 µm thickness for comprehensive histological examination. Tissue sections were mounted on glass slides and subjected to multiple staining protocols: Hematoxylin and eosin (H&E) for structural morphology assessment, Masson's trichrome for collagen quantification, and Herovici staining for differentiation between mature type I collagen and immature type III collagen. Histomorphological evaluation was conducted using an optical microscope (Olympus, Japan). Quantitative analysis of collagen density parameters was performed via ImageJ software (National Institutes of Health, USA). The ex vivo collagen quantification analysis was performed on n = 3 independent human‐derived skin samples. For each sample, three non‐overlapping microscopic fields were imaged under identical settings. These images were then analyzed using ImageJ software, applying a standardized thresholding method to quantify collagen deposition. Both Masson's trichrome staining and Herovici's staining were used to visualize collagen fibers. For each staining method, the mean grayscale intensity of collagen‐positive areas was measured per image, and the average of the three images per sample was used to generate a representative value. Statistical analysis was conducted based on these averaged values (n = 3/side). Relative change rates were calculated using the formula: Collagen density change rate (%) = [(Exo‐V side collagen density—control side collagen density) / control side collagen density] × 100%.
2.9. Statistical Analysis
All statistical analyses were performed using SPSS software version 20.0 (IBM Corp, Armonk, NY, United States). Normality of data distribution was assessed using the Shapiro‐Wilk test, as well as kurtosis and skewness values. For longitudinal comparisons across different assessment time points and between treatment sides in the split‐face design, two‐way repeated measures analysis of variance (two‐way repeated measures ANOVA) was used. Baseline comparisons between the Exo‐V side and control side were analyzed using the paired sample t‐test. When significant main effects or interaction effects were identified, post hoc multiple comparisons were performed. The significance level for all statistical analyses was set at p < 0.05.
3. RESULTS
3.1. Demographic Characteristics and Baseline Measurements
A total of 24 adult participants meeting the predetermined inclusion and exclusion criteria were initially enrolled in the study. Three participants were subsequently withdrawn, resulting in a final evaluable cohort of 21 individuals who completed the entire study protocol, as illustrated in Figure 1.
FIGURE 1.

Flowchart of participants.
Comprehensive demographic and skin‐related characteristics were systematically collected through a structured questionnaire survey and comprehensively documented in Table 1. The participant population demonstrated a mean age of 49.33 ± 4.73 years, with an age range spanning 42–58 years. Additionally, three instances of “environmental irritation” noted in Table 1 represent minor, transient skin reactions occurring before the intervention and determined to be unrelated to the study treatment. All symptoms resolved spontaneously, and the participants remained eligible for inclusion in the study. Preliminary baseline assessments of facial skin characteristics were conducted bilaterally, revealing no statistically significant differences between the left and right facial hemispheres (p > 0.05), thereby ensuring comparability before intervention, as detailed in Table 2.
TABLE 1.
Demographic information.
| Characteristic | N | Percentage (%) | Mean ± SD |
|---|---|---|---|
| Age (years) | 49.33 ± 4.73 | ||
| Sex | |||
| Male | 3 | 14.3 | |
| Female | 18 | 85.7 | |
| Skin type | |||
| Dry | 10 | 47.6 | |
| Normal | 5 | 23.8 | |
| Combination | 6 | 28.6 | |
| Smoking status | |||
| Non‐smoker | 20 | 95.2 | |
| <10 cigarettes/day | 1 | 4.8 | |
| Daily UV exposure | |||
| <1 h | 9 | 42.9 | |
| 1–3 h | 11 | 52.4 | |
| >3 h | 1 | 4.8 | |
| Baseline skin symptom history | |||
| Environmental irritation | 3 | 14.3 | |
| Stinging sensation | 2 | 9.5 | |
| Skin sensitivity | 4 | 19.0 | |
TABLE 2.
Baseline for Efficacy Evaluation Indicators.
|
Exo‐V side (n = 21) |
Control side (n = 21) |
p‐value a | |
|---|---|---|---|
| Wrinkle depth (mm) | 0.0474 ± 0.0120 | 0.0486 ± 0.0127 | 0.693 |
| Skin lifting (Angle) | 57.69 ± 11.16 | 56.42 ± 9.04 | 0.556 |
| Skin elasticity (R2) | 69.51 ± 4.38 | 67.91 ± 6.09 | 0.102 |
| Moisturizing effect (A.U.) | 32.71 ± 3.99 | 32.98 ± 3.80 | 0.681 |
| Skin tone (L*) | 69.51 ± 3.09 | 62.30 ± 3.12 | 0.310 |
| Pore area (mm2) | 0.1402 ± 0.0366 | 0.1448 ± 0.0307 | 0.271 |
| Skin texture (Ra, µm) | 7.19 ± 1.53 | 7.50 ± 1.78 | 0.242 |
| Skin glossiness (G.U.) | 6.93 ± 0.73 | 6.87 ± 0.77 | 0.420 |
| Transepidermal water loss (g/m2·h) | 17.00 ± 4.04 | 16.93 ± 3.84 | 0.592 |
Values are presented as mean ± SD.
Analyzed by paired t‐test between two sides.
3.2. Objective Assessment of Skin Improvement
3.2.1. Wrinkle Improvement Assessment
Wrinkle depth decreased over time on both sides, with a greater reduction on the Exo‐V side than on the control side (Figure 2A). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 23.2, p < 0.0001), treatment side (F(1,20) = 11.2, p = 0.0032), and assessment time point × treatment side interaction (F(5,100) = 4.88, p = 0.0005). Post hoc comparisons showed significantly lower wrinkle depth on the Exo‐V side than on the control side at later visits, as indicated in Figure 2A. The relative reductions on the Exo‐V side were 21.77%, 29.66%, and 26.94% at Visit 3, Visit 4, and the final visit, respectively, compared with 3.99%, 12.23%, and 12.04% on the control side. Representative 3D wrinkle images are shown in Figure 2D.
FIGURE 2.

Instrument‐Based Assessments of Skin Wrinkles, Lifting, and Elasticity. Evaluation of A: Skin wrinkles, B: Skin lifting, and C: Skin elasticity (R2) on both the Exo‐V side and control side at baseline and all evaluation phases. D: 3D imaging of skin wrinkles on the Exo‐V and control sides in a 53‐year‐old male participant. E: Imaging of skin lifting effects on the Exo‐V and control sides in a 56‐year‐old female participant. Lowercase a indicates comparisons versus baseline within each side, and lowercase b indicates comparisons between the two sides at the same assessment time point. a/b, p < 0.05; aa/bb, p < 0.01; aaa/bbb, p < 0.001. Data are presented as mean ± SD.
3.2.2. Skin Lifting Effect Assessment
Skin lifting angle decreased over time, with a greater reduction observed on the Exo‐V side during follow‐up (Figure 2B). Two‐way repeated‐measures ANOVA showed a significant effect of assessment time point (F(5,100) = 18.65, p < 0.0001) and a significant assessment time point × treatment side interaction (F(5,100) = 10.63, p < 0.0001), whereas the overall effect of treatment side was not significant (F(1,20) = 0.9522, p = 0.3408). Post hoc comparisons showed significant reductions from baseline on the Exo‐V side and significant between‐side differences at later visits, as indicated in Figure 2B. The relative reductions on the Exo‐V side were 5.70%, 4.23%, 10.09%, 11.72%, and 13.13% at Visit 1, Visit 2, Visit 3, Visit 4, and the final visit, respectively, whereas the corresponding reductions on the control side were 3.50%, 1.97%, 1.69%, 2.26%, and 3.23%. Representative lifting images are shown in Figure 2E.
3.2.3. Skin Elasticity Assessment
Skin elasticity increased over time on both sides, with a greater increase on the Exo‐V side than on the control side (Figure 2C). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 70.53, p < 0.0001), treatment side (F(1,20) = 24.67, p < 0.0001), and assessment time point × treatment side interaction (F(5,100) = 9.626, p < 0.0001). Post hoc comparisons showed significantly higher skin elasticity on the Exo‐V side than on the control side during follow‐up, as indicated in Figure 2C. The relative increases on the Exo‐V side were 12.66%, 4.52%, 6.54%, 8.62%, and 9.53% at Visit 1, Visit 2, Visit 3, Visit 4, and the final visit, respectively, compared with 6.19%, 2.32%, 3.50%, 4.50%, and 4.77% on the control side.
3.2.4. Moisturizing Effect Assessment
Moisturizing effect increased over time on both sides, with greater improvement on the Exo‐V side than on the control side (Figure 3A). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 933.4, p < 0.0001), treatment side (F(1,20) = 218.5, p < 0.0001), and assessment time point × treatment side interaction (F(5,100) = 97.30, p < 0.0001). Post hoc comparisons showed significant within‐side increases from baseline and significant between‐side differences at follow‐up visits, as indicated in Figure 3A. Descriptively, the Exo‐V side showed improvements of 142.79%, 42.91%, 44.57%, and 46.91% at Visit 1, Visit 3, Visit 4, and the final visit, respectively, compared with 94.56%, 28.15%, 19.22%, and 16.45% on the control side.
FIGURE 3.

Instrument‐Based Assessments of Skin Hydration, Skin Tone (Brightness), and Pore Area. Evaluation of A: Skin hydration, B: Skin tone (brightness), and C: Pore area on both the Exo‐V side and control side at baseline and all evaluation phases. D: Imaging of skin tone (brightness) on the Exo‐V and control sides in a 56‐year‐old female participant. E: Imaging of pore area on the Exo‐V and control sides in a 50‐year‐old female participant. Lowercase a indicates within‐side comparisons versus baseline, and lowercase b indicates between‐side comparisons at the same assessment time point. a/b, p < 0.05; aa/bb, p < 0.01; aaa/bbb, p < 0.001. Data are presented as mean ± SD.
3.2.5. Skin Tone (Brightness) Assessment
Skin tone increased over time on both sides, with greater improvement on the Exo‐V side than on the control side (Figure 3B). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 20.46, p < 0.0001), treatment side (F(1,20) = 25.24, p < 0.0001), and assessment time point × treatment side interaction (F(5,100) = 10.14, p < 0.0001). Post hoc comparisons showed significant within‐side increases from baseline and significant between‐side differences during follow‐up, as indicated in Figure 3B. Descriptively, the Exo‐V side showed increases of 4.58%, 2.27%, 3.29%, 4.11%, and 4.89% at Visit 1, Visit 2, Visit 3, Visit 4, and the final visit, respectively, compared with 3.13%, 1.21%, 1.75%, 2.33%, and 3.03% on the control side. Representative skin tone images are shown in Figure 3D.
3.2.6. Pore Area Assessment
Pore area decreased over time on both sides, with greater reduction on the Exo‐V side than on the control side (Figure 3C). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 29.72, p < 0.0001), treatment side (F(1,20) = 38.74, p < 0.0001), and assessment time point × treatment side interaction (F(5,100) = 5.676, p = 0.0001). Post hoc comparisons showed significant within‐side reductions from baseline and significant between‐side differences during follow‐up, as indicated in Figure 3C. Descriptively, the Exo‐V side showed reductions of 40.48%, 45.35%, and 43.37% at Visit 3, Visit 4, and the final visit, respectively, compared with 21.00%, 18.70%, and 28.41% on the control side. Representative pore images are shown in Figure 3E.
3.2.7. Skin Texture Assessment
Skin texture decreased over time on both sides, with greater reduction on the Exo‐V side than on the control side (Figure 4A). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 15.32, p < 0.0001), treatment side (F(1,20) = 18.40, p = 0.0004), and assessment time point × treatment side interaction (F(5,100) = 5.182, p = 0.0003). Post hoc comparisons showed significant within‐side reductions from baseline and significant between‐side differences during follow‐up, as indicated in Figure 4A. Descriptively, the Exo‐V side showed reductions of 20.77% and 19.15% at Visit 4 and the final visit, respectively, compared with 7.71% and 10.51% on the control side. Representative skin texture images are shown in Figure 4D.
FIGURE 4.

Instrument‐Based Assessments of Skin Texture, Glossiness (Radiance), and TEWL. Evaluation of A: Skin texture, B: Skin glossiness (radiance), and C: TEWL on both the Exo‐V side and control side at baseline and all evaluation phases. D: Imaging of skin texture on the Exo‐V and control sides in a 50‐year‐old female participant. Lowercase a indicates within‐side comparisons versus baseline, and lowercase b indicates between‐side comparisons at the same assessment time point. a/b, p < 0.05; aa/bb, p < 0.01; aaa/bbb, p < 0.001. Data are presented as mean ± SD.
3.2.8. Skin Glossiness (Radiance)Assessment
Skin glossiness increased over time on both sides, with greater improvement on the Exo‐V side than on the control side (Figure 4B). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 173.1, p < 0.0001), treatment side (F(1,20) = 175.0, p < 0.0001), and assessment time point × treatment side interaction (F(5,100) = 42.49, p < 0.0001). Post hoc comparisons showed significant within‐side increases from baseline and significant between‐side differences throughout follow‐up, as indicated in Figure 4B.
3.2.9. TEWL Assessment
TEWL decreased over time on both sides, with greater reduction on the Exo‐V side than on the control side (Figure 4C). Two‐way repeated‐measures ANOVA showed significant effects of assessment time point (F(5,100) = 70.35, p < 0.0001), treatment side (F(1,20) = 43.56, p < 0.0001), and assessment time point × treatment side interaction (F(5,100) = 10.87, p < 0.0001). Post hoc comparisons showed significant within‐side reductions from baseline and significant between‐side differences during follow‐up, as indicated in Figure 4C. Descriptively, the Exo‐V side showed reductions of 19.17%, 26.83%, 31.64%, and 36.91% at Visit 2, Visit 3, Visit 4, and the final visit, respectively, compared with 10.05%, 17.70%, 23.09%, and 27.87% on the control side.
3.3. Subjective Satisfaction Score
The questionnaire assessment of the perceived efficacy and user experience of the test product revealed that, at the final evaluation phase, all participants provided positive feedback across all evaluation items (Table 3).
TABLE 3.
Survey evaluation results on efficacy and usability.
| Item (After using Exo‐V) | Number (n) | Response rate (%) |
|---|---|---|
| Improvement in skin wrinkles | 21 | 100.00 |
| Increase in skin elasticity | 21 | 100.00 |
| Enhancement of skin hydration | 21 | 100.00 |
| Lifting effect on the skin | 21 | 100.00 |
| Improvement in skin radiance (luster) | 21 | 100.00 |
| Brightening of skin tone | 21 | 100.00 |
| Reduction in pore size | 21 | 100.00 |
| Decrease in frequency of skin troubles | 21 | 100.00 |
| Relief of skin heat sensation | 21 | 100.00 |
| Refinement and smoothing of skin texture | 21 | 100.00 |
| Overall satisfaction with the Exo‐V | 21 | 100.00 |
Note: Responses were recorded using a 5‐point Likert scale (1 = Very Unsatisfied, 2 = Unsatisfied, 3 = Neutral, 4 = Satisfied, 5 = Very Satisfied). For analysis, ratings of 3, 4 and 5 were categorized as “positive feedback.”.
3.4. Assessment of Adverse Skin Reactions
Throughout the study period, no participants experienced any adverse skin reactions.
3.5. Ex Vivo Experiment and Histopathological Evaluation
Structural morphology remained comparable between experimental and control sides across all evaluation timepoints (Figure 5A). However, the Exo‐V side demonstrated enhanced collagen synthesis, with substantially increased collagen deposition characterized by intense, uniform blue staining (Figure 5B). Quantitative assessment confirmed statistically significant elevation in collagen density: 13.36% higher at day 3 and 19.63% higher at day 7 relative to controls (p < 0.05) (Figure 5D). Neocollagen formation similarly increased in the Exo‐V side, evidenced by expanded blue‐stained dermal regions (Figure 5C). Quantitative analysis corroborated significantly increased neocollagen density of 54.52% and 57.41% at days 3 and 7, respectively, compared to controls (p < 0.05) (Figure 5E).
FIGURE 5.

Histological staining images of two sides (magnification: X200, scale bar: 100 µm). A: Hematoxylin and Eosin Staining. B: Masson's Trichrome Staining. C: Herovici's Staining. Quantitative results of D: collagen density and E: Young collagen density. The data presented are empirical findings obtained from three samples in each side (n = 3). Results are presented as mean ± SD. Lowercase a indicates significant differences between groups at the corresponding time point (a, p < 0.05; aa, p < 0.01).
4. DISCUSSION
From a clinical perspective, the current study provides compelling evidence that the combination of apple‐derived exosomes (Exo‐V Professional) and microneedling significantly enhances multiple parameters of facial skin quality, including elasticity, hydration, wrinkle depth, and barrier function. These improvements were consistently observed across both instrumental measurements and subjective participant feedback, with a 100% satisfaction rate and no reported adverse events. Such outcomes support the therapeutic potential of Exo‐V as a non‐invasive, well‐tolerated approach to facial rejuvenation. Moreover, the reduction in TEWL and improvement in skin sensitivity indirectly suggest enhanced barrier repair, which is particularly relevant for aging or environmentally stressed skin. Histological evidence of increased collagen deposition supports the potential extension of this strategy beyond healthy skin to aging, damaged, or regenerating tissues.
The observed efficacy of Exo‐V in enhancing skin quality may be attributed to the biological activity of its core component—apple‐derived exosomes. To elucidate the mechanistic basis for these effects, it is necessary to examine current evidence regarding exosome‐mediated pathways in cutaneous repair and rejuvenation. Exosomes are nano‐sized vesicles, ranging from 30 to 150 nm in diameter, enclosed by lipid bilayer membranes and actively secreted by various cell types [21, 22, 23]. These structures mediate intercellular communication through the transport of bioactive molecules, including proteins, lipids, mRNAs, and miRNAs [24, 25]. In mammalian systems, exosomes serve critical regulatory functions in immune responses, tissue repair, and cellular proliferation [26, 27, 28].
Plant‐derived nanovesicles (PDNVs) represent a recent advancement in extracellular vesicle research, demonstrating cross‐kingdom communication capabilities through plant‐specific miRNAs and distinctive lipid compositions that modulate mammalian cellular pathways [29, 30, 31]. These vesicles function as intrinsic plant defense mechanisms against environmental stressors. The exceptional biocompatibility of PDNVs with mammalian systems, characterized by the absence of cytotoxicity and adverse immune responses, positions them as optimal candidates for topical applications [30, 32]. Rigorous experimental studies have consistently demonstrated that these vesicles do not induce cytotoxicity or trigger adverse immune reactions when introduced to mammalian cells. This favorable safety profile positions them as ideal candidates for topical applications in cosmetic formulations and dermatological treatments, contexts in which repeated exposure is often necessary. Furthermore, their natural biological origin and relatively low production costs enhance their appeal as sustainable and environmentally responsible therapeutic agents for commercial development.
Chronic inflammation represents a central pathophysiological mechanism underlying numerous dermatological conditions and contributes significantly to skin aging processes [33, 34, 35]. Plant‐derived exosomes have consistently demonstrated robust anti‐inflammatory properties across multiple experimental models. For instance, nanovesicles derived from grapefruit and ginger have been shown to effectively reduce the production of reactive oxygen species (ROS) in target cells and inhibit the secretion of pro‐inflammatory cytokines that perpetuate inflammatory cascades. Apple‐derived nanovesicles (ADNVs) exemplify this anti‐inflammatory potential through specific molecular mechanisms. Studies have verified that ADNVs are biologically safe and exert significant anti‐inflammatory effects primarily through the induction of miRNA‐146 expression in M2‐polarized macrophages. This specific miRNA plays a crucial regulatory role in downregulating genes involved in the NF‐κB signaling pathway, a central mediator of inflammatory responses [19]. Through attenuating this signaling cascade, apple exosomes effectively reduce the production of key pro‐inflammatory cytokines including tumor necrosis factor‐alpha (TNF‐α), interleukin‐1 beta (IL‐1β), and interleukin‐6 (IL‐6). This gene regulatory function not only mitigates chronic inflammatory processes but also fosters a more balanced skin microenvironment that promotes tissue repair and regeneration. The skin's exposure to environmental stressors creates an oxidative environment that significantly contributes to cellular damage and premature aging. Apple‐derived exosomes have demonstrated inherent antioxidant properties that effectively combat oxidative stress in cutaneous tissues. Detailed proteomic analyses have revealed that ADNVs transport enzymes such as peroxidases and superoxide dismutase (SOD), which directly neutralize reactive oxygen species. In experimental studies with human dermal fibroblasts, ADNVs reduced mitochondrial superoxide levels by approximately 50% at concentrations ranging from 200 to 300 µg/mL, demonstrating clear dose‐dependent antioxidant activity [36]. These findings parallel observations from studies of grapefruit‐derived exosomes (GEVs), which have been shown to attenuate ROS production in macrophages and keratinocytes through the delivery of bioactive flavonoids and sphingolipids [37, 38]. The antioxidant activity of these plant‐derived vesicles is particularly significant for preserving the structural integrity of collagen and elastin fibers, which are essential components for maintaining skin elasticity, firmness, and youthful appearance.
Beyond their anti‐inflammatory and antioxidant properties, ADNVs actively contribute to skin regeneration processes by stimulating collagen production and mitigating the degradation of extracellular matrix (ECM) components. In fibroblast culture models, ADNVs have been shown to reduce ROS‐induced damage, which is critical for maintaining collagen structural integrity. A previous study demonstrated that ADNVs increase collagen synthesis by approximately 30% in UV‐irradiated fibroblasts, likely through mechanisms involving the downregulation of matrix metalloproteinases (MMPs) that typically degrade collagen fibers [36]. This regenerative capacity is further supported by lipidomic analyses indicating that ADNVs are enriched in lysophospholipids, which enhance cellular membrane fluidity and promote cellular repair mechanisms [39]. These specialized lipids demonstrate anti‐apoptotic properties, protecting keratinocytes from environmental stressors including pollution and UV radiation while preserving dermal structural integrity essential for skin elasticity and firmness. Skin barrier integrity is fundamental for preventing transepidermal water loss and pathogen infiltration. Plant‐derived exosomes support barrier maintenance and repair through delivery of specialized lipids and miRNAs that stimulate synthesis of barrier‐forming proteins and structural lipids. Apple exosomes, with their abundant bioactive lipid content, enhance ceramide and sphingolipid production critical for epidermal barrier function. These improvements result in enhanced hydration, reduced sensitivity, and strengthened natural defenses against environmental insults.
The integration of plant‐derived exosomes with advanced delivery systems such as microneedle therapy further enhances their therapeutic potential. These systems often incorporate complementary bioactive compounds such as ascorbic acid (vitamin C), which provides additional benefits for skin health. Ascorbic acid interferes with melanin synthesis through multiple mechanisms, most notably by targeting tyrosinase—the enzyme responsible for converting tyrosine into dopaquinone, a critical step in melanin production [40, 41]. As an effective reducing agent, ascorbic acid can reduce dopaquinone back to dihydroxyphenylalanine (DOPA), thereby interrupting the biochemical pathway leading to melanin polymerization. Furthermore, tyrosinase exhibits optimal enzymatic activity at near‐neutral pH conditions and becomes progressively less active under acidic conditions (pH below 5.5) [42]. The presence of ascorbic acid in microneedle formulations creates a mildly acidic microenvironment that further suppresses tyrosinase activity, enhancing the skin‐brightening effects. Beyond its role in melanin regulation, ascorbic acid performs significant antioxidative functions by donating electrons to reactive oxygen species such as hydroxyl radicals and superoxide anions, effectively neutralizing these harmful molecules before they can damage cellular components including DNA, proteins, and lipids. This protective mechanism reduces the cascade of oxidative stress events that contribute to inflammation and photoaging in cutaneous tissues.
Despite the encouraging results, this study has several important limitations. First, the clinical study was not randomized, as treatment allocation was predefined by facial side rather than assigned through randomization. Therefore, laterality‐related bias and residual confounding cannot be completely excluded. Second, although the observed improvements were statistically significant, the relatively small sample size (n = 21) and the short 12‐week follow‐up period may restrict the generalizability of the findings and limit assessment of long‐term efficacy or delayed adverse effects. Third, no formal wash‐off period was included before treatment initiation. Although participants with recent cosmetic procedures, laser treatment, tanning, or comparable clinical study participation were excluded and the use of new functional skincare products was restricted during the study period, the possible residual influence of previously used skincare products cannot be completely excluded. Fourth, the absence of cytokine profiling or immune marker analysis limited the ability to elucidate the underlying inflammatory or immunomodulatory mechanisms associated with collagen remodeling. Fifth, the control side used saline rather than a vehicle‐matched formulation; given that ingredients in Component 2 (e.g., hyaluronic acid) may exert bioactive effects, the lack of a dedicated vehicle‐only control impairs precise attribution of efficacy to exosomes. Lastly, although standardized instructions were provided, the reliance on subjective participant ratings may have introduced reporting bias.
5. CONCLUSION
In conclusion, this prospective split‐face self‐controlled study showed that topical application of Exo‐V Professional after microneedling was associated with greater short‐term improvements in wrinkles, lifting, elasticity, hydration, skin brightness, pore area, texture, glossiness, TEWL, and collagen deposition compared with microneedling plus saline. However, given the complex composition of the final formulation and the absence of exosome‐only, microneedling‐only, no‐microneedling, and vehicle‐matched comparator groups, these findings should be interpreted as preliminary clinical evidence rather than definitive proof of the isolated efficacy of apple‐derived exosomes. Further randomized, blinded, and controlled studies are needed to validate these results and clarify the specific contribution of each component.
Conflicts of Interest
The authors declare no competing interests in this study.
Ethical Statement
This study has been approved by the Institutional Review Board of the Korea Skin Clinical Research Center (KSRC) (Approval No: HBABN01‐241016‐HR‐E0044‐04) and the Institutional Review Board of the Korean Institute of Nonclinical Study (KINS) (Approval No: B‐2404‐893‐301).
Acknowledgments
This study was funded by the SNUBH Research Fund (Grant Number. 16‐2019‐0004).
Contributor Information
Chan Yeong Heo, Email: lionheo@snu.ac.kr.
Sang Hoon Park, Email: spark@idhospital.com.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Gravitz L., “Skin,” Nature 563, no. 7732 (2018): S83. [DOI] [PubMed] [Google Scholar]
- 2. Arda O., Göksügür N., and Tüzün Y., “Basic Histological Structure and Functions of Facial Skin,” Clinics in Dermatology 32, no. 1 (2014): 3–13. [DOI] [PubMed] [Google Scholar]
- 3. Khavkin J. and Ellis D. A., “Aging Skin: Histology, Physiology, and Pathology,” Facial Plastic Surgery Clinics of North America 19, no. 2 (2011): 229–234. [DOI] [PubMed] [Google Scholar]
- 4. de Moura J. P., de Moura Fernandes ÉP L. R. T. C. M., Messias Monteiro A. F., de Sousa N. F., and dos Santos A. M. F., “Targets Involved in Skin Aging and Photoaging and Their Possible Inhibitors: A Mini‐review,” Current Drug Targets 24, no. 10 (2023): 797–815. [DOI] [PubMed] [Google Scholar]
- 5. Salminen A., Kaarniranta K., and Kauppinen A., “Photoaging: UV Radiation‐induced Inflammation and Immunosuppression Accelerate the Aging Process in the Skin,” Inflammation Research 71, no. 7‐8 (2022): 817–831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Khetpal S., Ghosh D., and Roostaeian J., “Innovations in Skin and Soft Tissue Aging—A Systematic Literature Review and Market Analysis of Therapeutics and Associated Outcomes,” Aesthetic Plastic Surgery 47, no. 4 (2023): 1609–1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Kao C. C. and Duscher D., “Advanced Endoscopic Techniques in Asian Facial Rejuvenation,” Clinics in Plastic Surgery 50, no. 1 (2023): 51–60. [DOI] [PubMed] [Google Scholar]
- 8. Spataro E. A., Dierks K., and Carniol P. J., “Microneedling‐Associated Procedures to Enhance Facial Rejuvenation,” Clinics in Plastic Surgery 50, no. 3 (2023): 479–488. [DOI] [PubMed] [Google Scholar]
- 9. Krylova S. V. and Feng D., “The Machinery of Exosomes: Biogenesis, Release, and Uptake,” International Journal of Molecular Sciences 24, no. 2 (2023): 1337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Ha D. H., Kim H. K., Lee J., et al., “Mesenchymal Stem/Stromal Cell‐Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration,” Cells 9, no. 5 (2020): 1157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Wu J. Y., Wu S. N., Zhang L. P., et al., “Stem Cell‐Derived Exosomes: A New Method for Reversing Skin Aging,” Tissue Eng Regen Med 19, no. 5 (2022): 961–968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. An Y., Lin S., Tan X., et al., “Exosomes From Adipose‐derived Stem Cells and Application to Skin Wound Healing,” Cell Proliferation 54, no. 3 (2021): e12993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Kusnandar M. R., Wibowo I., and Barlian A., “Characterizing Nanoparticle Isolated by Yam Bean (Pachyrhizus erosus) as a Potential Agent for Nanocosmetics: An in Vitro and in Vivo Approaches,” Pharm Nanotechnol 13, no. 2 (2025): 341–357. [DOI] [PubMed] [Google Scholar]
- 14. Mu N., Li J., Zeng L., et al., “Plant‐Derived Exosome‐Like Nanovesicles: Current Progress and Prospects,” International Journal of Nanomedicine 18 (2023): 4987–5009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Huang D., Chen J., and Zhao M., “Plant‐derived Extracellular Vesicles: Composition, Function and Clinical Potential,” Journal of translational medicine 23, no. 1 (2025): 1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Majewska L., Dorosz K., and Kijowski J., “Efficacy of Rose Stem Cell‐Derived Exosomes (RSCEs) in Skin Treatment: From Healing to Hyperpigmentation Management: Case Series and Review,” Journal of Cosmetic Dermatology 24, no. 1 (2025): e16776. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Choi W., Cho J. H., Park S. H., et al., “Ginseng Root‐derived Exosome‐Like Nanoparticles Protect Skin From UV Irradiation and Oxidative Stress by Suppressing Activator Protein‐1 Signaling and Limiting the Generation of Reactive Oxygen Species,” Journal of Ginseng Research 48, no. 2 (2024): 211–219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Trentini M., Zanolla I., and Zanotti F., “Apple Derived Exosomes Improve Collagen Type I Production and Decrease MMPs During Aging of the Skin Through Downregulation of the NF‐κB Pathway as Mode of Action,” Cells 11, no. 24 (2022): 3950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Trentini M., Zanotti F., Tiengo E., et al., “An Apple a Day Keeps the Doctor Away: Potential Role of miRNA 146 on Macrophages Treated With Exosomes Derived From Apples,” Biomedicines 10, no. 2 (2022): 415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Jin Y. X., Ngoc Chien P., and Thi Nga P., “Enhancing Wound Healing Through Innovative Technologies: Microneedle Patches and Iontophoresis,” Frontiers in Bioengineering and Biotechnology 12 (2024): 1468423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Gurung S., Perocheau D., Touramanidou L., and Baruteau J., “The Exosome Journey: From Biogenesis to Uptake and Intracellular Signalling,” Cell Communication and Signaling 19, no. 1 (2021): 47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Jeppesen D. K., Zhang Q., Franklin J. L., and Coffey R. J., “Extracellular Vesicles and Nanoparticles: Emerging Complexities,” Trends in Cell Biology 33, no. 8 (2023): 667–681. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Sonbhadra S. and Mehak P. L. M., “Biogenesis, Isolation, and Detection of Exosomes and Their Potential in Therapeutics and Diagnostics,” Biosensors (Basel) 13, no. 8 (2023): 802. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Tenchov R., Sasso J. M., Wang X., Liaw W. S., Chen C. A., and Zhou Q. A., “Exosomes Horizontal Line Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics,” ACS Nano 16, no. 11 (2022): 17802–17846. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Javdani‐Mallak A. and Salahshoori I., “Environmental Pollutants and Exosomes: A New Paradigm in Environmental Health and Disease,” Science of the Total Environment 925 (2024): 171774. [DOI] [PubMed] [Google Scholar]
- 26. Kumar M. A., Baba S. K., Sadida H. Q., et al., “Extracellular Vesicles as Tools and Targets in Therapy for Diseases,” Signal Transduct Target Ther 9, no. 1 (2024): 27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Lou G., Chen Z., Zheng M., and Liu Y., “Mesenchymal Stem Cell‐derived Exosomes as a New Therapeutic Strategy for Liver Diseases,” Experimental & Molecular Medicine 49, no. 6 (2017): e346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Fan M. H., Pi J. K., Zou C. Y., et al., “Hydrogel‐exosome System in Tissue Engineering: A Promising Therapeutic Strategy,” Bioact Mater 38 (2024): 1–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Lian M. Q., Chng W. H., Liang J., et al., “Plant‐derived Extracellular Vesicles: Recent Advancements and Current Challenges on Their Use for Biomedical Applications,” Journal of Extracellular Vesicles 11, no. 12 (2022): e12283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Nemati M., Singh B., Mir R. A., et al., “Plant‐derived Extracellular Vesicles: A Novel Nanomedicine Approach With Advantages and Challenges,” Cell Communication and Signaling 20, no. 1 (2022): 69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Yi Q., Xu Z., Thakur A., et al., “Current Understanding of Plant‐derived Exosome‐Like Nanoparticles in Regulating the Inflammatory Response and Immune System Microenvironment,” Pharmacological Research 190 (2023): 106733. [DOI] [PubMed] [Google Scholar]
- 32. Zhao B., Lin H., Jiang X., et al., “Exosome‐Like Nanoparticles Derived From Fruits, Vegetables, and Herbs: Innovative Strategies of Therapeutic and Drug Delivery,” Theranostics 14, no. 12 (2024): 4598–4621. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Chen Y. and Lyga J., “Brain‐skin Connection: Stress, Inflammation and Skin Aging,” Inflamm Allergy Drug Targets 13, no. 3 (2014): 177–190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Metz M. and Stander S., “Chronic Pruritus–pathogenesis, Clinical Aspects and Treatment,” Journal of the European Academy of Dermatology and Venereology 24, no. 11 (2010): 1249–1260. [DOI] [PubMed] [Google Scholar]
- 35. Shin S. H., Lee Y. H., Rho N. K., and Park K. Y., “Skin Aging From Mechanisms to Interventions: Focusing on Dermal Aging,” Front Physiol 14 (2023): 1195272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Trentini M., Zanolla I., Zanotti F., Tiengo E., and Licastro D., “Apple Derived Exosomes Improve Collagen Type I Production and Decrease MMPs During Aging of the Skin Through Downregulation of the NF‐kappaB Pathway as Mode of Action,” Cells 11, no. 24 (2022): 3950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Mu N., Li J., Zeng L., et al., “Plant‐Derived Exosome‐Like Nanovesicles: Current Progress and Prospects,” Int J Nanomedicine 18 (2023): 4987–5009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Huang R., Jia B., Su D., et al., “Plant Exosomes Fused With Engineered Mesenchymal Stem Cell‐derived Nanovesicles for Synergistic Therapy of Autoimmune Skin Disorders,” Journal of Extracellular Vesicles 12, no. 10 (2023): e12361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Trentini M., Zanolla I., Tiengo E., et al., “Link Between Organic Nanovescicles From Vegetable kingdom and human Cell Physiology: Intracellular Calcium Signalling,” J Nanobiotechnology 22, no. 1 (2024): 68. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Sanadi R. M. and Deshmukh R. S., “The Effect of Vitamin C on Melanin Pigmentation—A Systematic Review,” J Oral Maxillofac Pathol 24, no. 2 (2020): 374–382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Panzella L. and Napolitano A., “Natural and Bioinspired Phenolic Compounds as Tyrosinase Inhibitors for the Treatment of Skin Hyperpigmentation: Recent Advances,” Cosmetics [Internet] 6, no. 4 (2019): 57. [Google Scholar]
- 42. de Almeida Santos G., Englund A. N. B., Dalleywater E. L., and Rohr A. K., “Characterization of Two Bacterial Tyrosinases From the Halophilic Bacterium Hahella sp. CCB MM4 Relevant for Phenolic Compounds Oxidation in Wetlands,” FEBS Open Bio 14, no. 12 (2024): 2038–2058. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
